|
Test ID: BCR/ABL(DF) t(9;22)(q34;q11.2) by FISH
|
|
BCR/ABL(DF) t(9;22)(q34;q11.2) by FISH
|
|
BCR/ABL(DF) t(9;22)(q34;q11.2) by FISH
|
|
Method name and description
|
Interphase Fluorescence In Situ Hybridization (I-FISH) study.
|
|
Clinical information
|
BCR/ABL(DF) t(9;22)(q34;q11.2) by FISH is used for identifying a neoplastic clone correlated with a BCR/ABL1 rearrangement, in patients with Chronic Myeloid Leukemia (CML) and MPN. Following the percentage of nuclei with BCR/ABL1 rearrangement and response to therapy in patients with MPN/ CML.
|
|
|
Specimen type / Specimen volume / Specimen container
|
Specimen Type: Blood/Leukemic Blood
Container/Tube: Green top (sodium heparin)
Specimen Volume: 2-6 mL (Varies depending on the
WBC-Count).
(Adult - 3-6 mL ,Child - 2 mL, Infant - 2 mL)
Specimen Type: Bone marrow
Container/Tube: Bone Marrow Transport Media
Specimen Volume: 1-3 mL (Varies depending on the
WBC-Count).
|
|
Collection instructions / Special Precautions / Timing of collection
|
Sunday-Wednesday 7:00 -14:00
|
|
Storage and transport instructions
|
|
|
|
Specimen Rejection Criteria
|
Consistent with Diagnostic Genomic Division policies.
|
|
|
Factors affecting test performance and result interpretation
|
Fusion of BCR/ABL1 is observed in all patients with Chronic Myeloid Leukemia (CML), in roughly 25% of adult patients with precursor B-cell acute lymphoblastic leukemia (B-ALL) and in 1% of patients with pediatric B- ALL.
The chromosome component resulting in BCR/ABL1 fusion is a t(9;22)(q34;q11.2) in approximately 85%, a complex 9;22 translocations with 1 or more additional chromosomes in roughly 15% and a chromosomally "cryptic" or insertional translocation in less than 1% of patients.
|
|
Turnaround time / Days and times test performed / Specimen retention time
|
|
|
|
|
